The phase II German study SORMAIN tested the benefit of adding the tyrosine kinase inhibitor sorafenib as maintenance therapy in adult patients with FLT3-ITD AML who achieved a complete response (CR) after allogeneic stem cell transplantation (SCT) and found that sorafenib maintenance reduces disease relapse and death versus placebo by more than half [14]. Here, FLT3 is linked to acute myeloid leukemia.